The Daily Toke

March 29, 2026

# Cannabis Policy Shifts Accelerate Across States as Federal Framework Remains Fractured

The U.S. cannabis landscape is fragmenting in real time. While 16 federal bills sit in Congress—including the MORE Act with 62 sponsors—state legislatures are racing ahead with their own fixes, creating a patchwork that rewards some patients while leaving others behind. The Army's new recruitment policy allowing marijuana convictions signals a dramatic shift in how federal agencies view cannabis users, yet Congress still can't agree on basic federal rescheduling, leaving state programs, Medicare coverage, and international trade in legal limbo.

💰 MONEY MOVES Pennsylvania Gov. Josh Shapiro is banking on marijuana legalization to fill a $5 billion budget shortfall, projecting $729 million in new revenue next fiscal year—but the legislature remains deadlocked on which agency should regulate it. Republican Sen. Dan Laughlin wants a new Cannabis Control Board; Democratic Rep. Dan Frankel prefers the Liquor Control Board. Neither side will budge. Meanwhile, Whitney Economics projects U.S. legal marijuana sales will rebound to $30.5 billion in 2026 after the market's first-ever revenue decline in 2025, with growth accelerating to $43.3 billion by 2030. That maturation is real: the era of explosive growth is over. Pricing compression and supply saturation are now the dominant forces. New York and Ohio's expanded retail access kept the entire market afloat last year.

Georgia's House voted 144-21 to expand medical marijuana access—removing the "low THC" cap that confused patients into thinking they were getting inferior products—while Mississippi passed bills to eliminate potency caps on cannabis oils and allow a "Right to Try" pathway for patients outside the qualifying conditions list. Idaho activists have qualified a medical marijuana ballot measure projected to generate $100 million in annual sales and up to $28 million in state revenue by year six. 🚀 THIS IS COOL Hawaii's House committee unanimously advanced legislation to create a psychedelics task force studying psilocybin and MDMA access for veterans and trauma survivors—the Senate already passed it 24-0—while Massachusetts lawmakers are publicly skeptical of a ballot initiative that would roll back the state's 2016 legalization, with legislator Michael Day pointing out the proposal would create exactly the black market its supporters claim to oppose.

But progress halts at the federal line. 🔎 DOUBLE STANDARD WATCH Pennsylvania Republican Rep. Kathy Rapp opposes legalization citing youth addiction and mental health risks, yet beer and liquor manufacturers donate to her campaign while alcohol kills roughly 95,000 Americans annually—including thousands of teenagers. Cannabis has zero recorded overdose deaths in human history. She points to impaired driving concerns while the Pennsylvania Driver's Manual warns that alcohol "seriously impairs your ability to drive safely." A JAMA study shows 10-30% of marijuana users develop cannabis use disorder; alcohol addiction affects 15% of American drinkers but kills 40 times more people per year. Her argument rests on protecting children from a zero-death product while the legal alternative kills tens of thousands annually. The contradiction is documented and measurable. Meanwhile, Rep. Dan Frankel remains open to Laughlin's Cannabis Control Board proposal, signaling compromise may still be possible.

House Judiciary Committee Ranking Member Jamie Raskin has warned that a separate bill to expedite deportations could classify teenagers who smoke marijuana in states where it's legal as members of a "criminal gang"—even if they're in full compliance with state law. The Centers for Medicare & Medicaid Services confirmed Medicare will cover hemp-derived CBD products starting April 1, allowing up to 3 milligrams of THC, though President Trump's recent hemp THC recriminalization bill could upend the entire pilot program. 🤔 THINK ABOUT IT Federal law still treats cannabis as Schedule I—no medical use, high abuse potential—while simultaneously launching a Medicare pilot to cover cannabis-derived medicine. Congress can't reschedule it. The Army is recruiting people with marijuana convictions. Thirty-plus states have legal medical programs. The WNBA is dropping marijuana testing. And yet 16 bills sit in Congress waiting for votes. This isn't policy anymore. It's institutional inertia meeting a changed country.

March 29, 2026

# HEMP BAN WATCH

Regulatory chaos is descending on America's hemp market as state-level crackdowns collide with federal deadlines, threatening an $8 billion industry and forcing thousands of retailers to choose between closure, litigation, or the illicit market. Texas is leading the charge: new rules from the Texas Department of State Health Services take effect March 31, capping total THC in smokable hemp products at 0.3 percent—a fundamental shift from prior law that focused solely on Delta-9 THC. This redefinition would effectively ban THCA-rich flowers and pre-rolls, products that currently dominate shelves at roughly 1,500 Texas hemp shops. The regulatory overhaul pairs the product ban with eye-popping fee increases: manufacturer licenses jump from $258 to $10,000 annually, while retail registrations rise from $155 to $5,000. 💰 MONEY MOVES Industry players warn the changes could cripple what they estimate is an $8 billion sector, forcing widespread closures among retailers dependent on high-margin smokable products.

The Texas hemp retailer Boomtown Vapor LLC has already filed a lawsuit in Travis County challenging the new "Total THC" standard, arguing the state health department is overstepping its authority by unilaterally redefining hemp law without legislative action. The plaintiff seeks a temporary restraining order to block enforcement, warning that without court intervention, thousands of small businesses face immediate closure and layoffs. A judge has not yet ruled on the request, and the deadline looms: April 1, 2026 is when the new rules become fully enforceable unless blocked. Meanwhile, edibles and beverages appear positioned to survive the crackdown, offering a potential lifeline for some retailers willing to pivot away from smokables—but the shift may not generate enough revenue to offset lost sales for shops built around higher-margin flower and pre-roll products. The regulatory overhaul follows a near-death experience last year, when lawmakers passed legislation that would have effectively banned hemp-derived THC products before Governor Greg Abbott issued a last-minute veto, directing state agencies to tighten oversight instead.

The Texas crackdown is not isolated. A federal provision in the spending bill would ban all hemp products containing more than 0.4 milligrams of psychoactive THC per container, with an effective date of November 12—creating an existential threat to the entire industry unless lawmakers act. Representative James Baird (R-Indiana) introduced H.R. 7010 to push that deadline to November 2028, while Representatives Morgan Griffith (R-Virginia) and Marc Veasey (D-Texas) co-sponsored the bipartisan Hemp Enforcement, Modernization and Protection (HEMP) Act, which would authorize FDA regulation of hemp-derived THC products rather than outright prohibition. Industry advocates argue the distinction matters: regulation offers a path forward; prohibition forces suppliers into the illicit market. Meanwhile, Ohio's hemp ban has already taken effect, clearing shelves at gas stations and convenience stores, while Pennsylvania lawmakers—frustrated by what State Senator Judy Schwank (D.) calls "the wild west" of unregulated hemp sales—are drafting new legislation to impose testing requirements, age restrictions, and enforcement penalties. 🤔 THINK ABOUT IT Pennsylvania's hemp shops exploit gray areas between federal and state law to sell products of unknown composition and potency, yet the state's proposal to legalize recreational marijuana includes no expedited timeline for regulation—leaving consumers in regulatory limbo while competitors in other states operate under clearer frameworks.

The hemp industry now faces a patchwork of state-level restrictions layered atop federal deadlines, each with different THC thresholds and enforcement timelines. Retailers in Texas must decide whether to sue, pivot to non-smokable products, or cease operations before March 31. Industry advocates emphasize that convenience store operators and hemp distributors must engage in state and federal advocacy if they want to continue selling these products—a call to action suggesting that regulation, not prohibition, remains the preferred path for many players with skin in the game. The market disruption is real: landlords with significant retail portfolios tied to hemp tenants face sudden revenue loss, while small business owners confront the choice between adaptation and closure. What remains unclear is whether federal lawmakers will act before November's deadline, whether courts will intervene in Texas, and whether states like Pennsylvania will move toward regulation or prohibition. For now, the hemp ban watch continues—with timelines tightening, legal challenges mounting, and an industry built on regulatory ambiguity facing pressure from multiple directions at once.

March 29, 2026

Researchers at the University of Sydney have delivered a sobering verdict on one of the most popular wellness trends in America: medicinal cannabis shows little strong evidence for treating mental health disorders or substance use conditions. The comprehensive review, published in The Lancet Psychiatry and analyzing 54 clinical trials spanning from 1980 to 2025, found no meaningful evidence that cannabinoid-based treatments work for anxiety, depression, or PTSD. Lead author Dr. Jack Wilson highlighted a more troubling concern—that cannabis use could actually delay patients from accessing genuinely effective treatments and may increase the risk of developing psychosis. 🚀 THIS IS COOL The one bright spot in the mental health data remains epilepsy, where CBD-dominant formulations have cleared the highest scientific bar, with FDA-approved Epidiolex showing sustained seizure reduction even at 144 weeks into extended follow-up studies. But for the millions of Americans self-medicating with cannabis for mood disorders, this research suggests they're likely masking symptoms rather than treating them.

The mental health findings land hard against the backdrop of federal policy shifts. The Centers for Medicare & Medicaid Services recently announced coverage for hemp-derived CBD products starting April 1, allowing up to 3 milligrams of THC per dose under a pilot program covering up to $500 annually for Medicare beneficiaries. 💰 MONEY MOVES Industry analysts estimate that CBD wellness products alone could reach between $8.5 billion and $13 billion in market sales in 2026, making this federal coverage announcement a significant validation of the market—even as scientists cast doubt on the mental health claims driving consumer adoption. However, that coverage framework is already under pressure: President Trump recently signed legislation to recriminalize hemp-derived THC products, which could shrink the allowable THC threshold and fundamentally reshape what Medicare will actually cover.

The question of how to regulate cannabis products without banning them entirely has triggered a federal controversy. Daniel Kruger, a cannabis policy researcher at the University at Buffalo, argues that an outright ban on CBD products—set to take effect by November under shutdown legislation—is unnecessary overreach that mistakes poor regulation for the need for prohibition. Kruger's research shows that delta-8 THC is most popular in states where legal delta-9 THC isn't accessible, suggesting that criminal bans drive consumers toward less-regulated alternatives rather than preventing use.

On the therapeutic side, evidence is more nuanced than marketing claims suggest. A new study published in the Journal of Pain Research found that 🚀 THIS IS COOL full-spectrum CBD-dominant extracts significantly outperformed synthetic THC (dronabinol) in older adults with chronic pain, with 85.7% of CBD users meeting the study's primary outcome (meaningful symptom improvement plus tolerability) compared to just 21.9% of the THC group. Adverse reactions were reported in 15.5% of the CBD group versus 35.7% in the THC group—a meaningful safety margin. Yet CBD-alone products for pain relief remain poorly studied; a 2026 Cochrane Review of 21 studies found no clear evidence that CBD alone achieves meaningful neuropathic pain relief. 🚀 THIS IS COOL The entourage effect—the theory that whole-plant cannabis works better than isolated compounds—has partial clinical support, particularly in epilepsy research where whole-plant extracts showed improvement 71% of the time versus 46% for purified CBD isolate. But this is far from settled science; several well-designed studies have produced contradictory findings, and the dose-response relationship for many applications may follow an inverted-U curve, meaning more isn't always better.

Beyond pain and mental health, early research points toward unexpected applications. Researchers at Hebrew University in Jerusalem found that cannabis compounds CBD and CBG improved liver function in mouse models of non-alcoholic fatty liver disease (NAFLD), a condition affecting roughly 24% of U.S. adults. The compounds appeared to enhance hepatic energy and lysosomal function, creating what researchers describe as dual metabolic remodeling. These are still early findings—mouse models don't automatically translate to humans—but they suggest mechanisms worth exploring. 💰 MONEY MOVES Meanwhile, formulation chemistry is advancing rapidly: a new study in the Journal of Pharmaceutical and Biomedical Analysis found that powder-based CBD formulations (using cyclodextrin complexes) retain over 90% of CBD under standard conditions compared to roughly 20% retention in oil when exposed to light, potentially extending shelf life and product consistency across the supply chain.

🤔 THINK ABOUT IT The gap between where cannabis science actually stands and where consumers believe it stands has never been wider. One in five American adults now uses CBD products, yet the FDA has approved exactly one CBD product—pharmaceutical-grade Epidiolex for epilepsy. Medicare is about to cover hemp products while Congress prepares to ban them. Mental health researchers are finding no evidence of benefit while millions self-treat for anxiety and depression. And veterans in states with strict THC limits face legal barriers to products that many have found helpful for PTSD and chronic pain. The cannabis normalization story isn't one of a miracle plant finally being recognized—it's one of a market that has moved faster than science, and a regulatory system that's struggling to catch up.

March 29, 2026

Smokable hemp products will disappear from Texas shelves March 31 when new state regulations take effect, capping THC in all cannabis-derived products at 0.3%—a threshold that effectively bans the joints, flower, and pre-rolled products that generate the majority of revenue for the state's hemp retailers. The Texas Department of State Health Services implemented the rules following Governor Greg Abbott's executive order last September, after he vetoed Senate Bill 3 last summer, which would have instituted an outright ban. The new regulations also impose a $5,000 annual retail registration fee and add extensive testing and labeling requirements that industry operators say will devastate a business sector that has operated legally under Texas law since 2019.

💰 MONEY MOVES The shift from a "Delta-9 THC" standard to a "Total THC" standard—combining Delta-9 and THCA—will render nearly all current inventory illegal overnight, according to Boomtown Vapor LLC, which filed a lawsuit March 17 seeking a temporary restraining order. The hemp retailer argues the DSHS is overstepping its authority by unilaterally redefining what constitutes legal hemp, a definition that has been statute since House Bill 1325 in 2019. David Burrow, CEO of San Antonio's Alamo Botanicals, stated that instead of an effective ban disguised as regulation, state officials should strengthen testing compliance to ensure products are accurately labeled and meet existing standards. Industry operators emphasize that thousands of small businesses face immediate closure and mass layoffs if the rules take effect as scheduled.

Brook Richie, owner of Bee's Wellness Cafe in San Antonio, captured the frustration felt across the industry: "You could already see it heading in this direction. It just seems to be unfair for the people of Texas, because state officials are basically telling them how they can get their medicine." The regulations come despite months of industry anticipation and despite Abbott's own 2025 veto statement warning that an outright THC ban was legally flawed. The inconsistency between the governor's reasoning last year and his current agency's effective prohibition through regulatory overreach now sits at the center of Boomtown Vapor's legal challenge, with a judge yet to rule on the restraining order that could prevent March 31 enforcement.

🤔 THINK ABOUT IT Texas operates under the assumption that dramatically restricting access to a zero-overdose product for legal adult users will improve public health outcomes, while maintaining unrestricted legal access to alcohol—which causes more than 95,000 deaths annually—and accepting campaign contributions from the industries that profit from both. What empirical health outcome is this regulation designed to achieve? The court will answer that question, but the legal and commercial landscape will shift dramatically on March 31 regardless, affecting an industry that has operated legally under state statute for seven years.